Development

Cynthia A. Challener, PhD, is a contributing editor to BioPharm International.

Articles

Advances in technology are accelerating the development and manufacture of subunit vaccines, an established class of vaccines.

Subunit Vaccines and the Fight Against COVID-19

Contract manufacturers play a key role in the production of lipid nanoparticles for RNA vaccines.

Meeting the Demand for Lipid Excipients 

DFE’s new line will offer market purity and low endotoxin excipients for use in formulation, while providing drug developers and manufacturers high-quality excipient technology and services. 

DFE Pharma to Launch New Biopharma Excipient Solution 

The company will join the network of approved manufacturers of the lipid excipients. 

AMRI to Develop and Manufacture Lipid Excipients for Pfizer-BioNTech COVID-19 Vaccine

A newly developed polymer, DynaShield, may have the capability to ensure global access for COVID-19 treatment and prevention.

Helena Offers Polymer Solution to Global Cold Chain Issues for COVID-19 Vaccines, Biologics, and Therapeutics

With the acquisition, Evonik will expand its life science division and its portfolio of functional excipients and biomaterials. 

Evonik to Acquire Birmingham-Based LACTEL Absorbable Polymers from DURECT Corporation

At the 2020 Bio/Pharma Virtual Congress, experts discuss the importance of characterizing excipients to ensure quality, safety, and effective performance. 

Understanding Excipient Quality and Impact on Formulation

CordenPharma announces expansion of lipid excipients supply for coronavirus vaccine scale up.

CordenPharma Expands Lipid Supply for Moderna

USP technical advisors will offer assistance to drug developers to ensure material quality and testing.

USP Offers Support for COVID-19 Drug Developers

The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.